Clinical Trial: A Clinical Study of the HCMV-TB Vaccine Candidate VIR-1778 in Healthy Adults

U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07818824) titled 'A Clinical Study of the HCMV-TB Vaccine Candidate VIR-1778 in Healthy Adults' on Aug. 05.

Brief Summary: This Phase 1, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and immune responses of the investigational HCMV-TB vaccine candidate VIR-1778 in adults in overall good health without HIV who are cytomegalovirus (CMV) seropositive. Participants will receive two doses of either VIR-1778 or placebo administered 12 weeks apart. The study will assess the safety of VIR-1778, its ability to induce immune responses against Mycobacterium tuberculosis (TB) antigens, and the presence of vaccine-der...